Terumo Corporation (TRUMY) Stock Price & Analysis
Terumo Corporation (TRUMY) — price $16.20 (+3.05%), as of the Nov 19, 2026 trading session; market cap $23.9B.
Educational signal · not a buy or sell recommendation · How to read this
Terumo Corporation · TRUMY · Healthcare · Medical - Devices
Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular…
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $16.20 | |
| Change on the day | +3.05% | |
| 52-week range | $12.08–$16.81 | |
| Market capitalisation | $23.9B | — |
| Price / earnings (trailing) | 33.04 | |
| Shares traded on the day | 5.9K | |
| Beta (volatility vs the S&P 500) | 0.23 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Terumo (TRUMY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
1 lens, 1 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Terumo (TRUMY), and what does it report?
Short answer
Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular… Healthcare / Medical Devices Headquarters: 2-44-1, Hatagaya, Tokyo, TY, 151-0072, JP. It employs 30,207 people and is led by Hikaru Samejima. In Q2 FY2027 it reported revenue of ¥312.47B and net income of -¥15.80B. The market values it at $23.9B.
What do the latest results show for Terumo (TRUMY)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ¥312.47B. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ¥312.47B | -¥15.80B | -¥10.71 (diluted) |
| Q1 FY2027 | ¥311.81B | ¥70.43B | ¥47.73 (diluted) |
| Q4 FY2026 | ¥305.84B | ¥26.85B | ¥17.58 (diluted) |
| Q3 FY2026 | ¥301.98B | ¥33.24B | ¥21.96 (diluted) |
What are the financial strengths and risks for Terumo (TRUMY)?
Short answer · as of
The distress and quality screens read Altman Z 5.29 · Piotroski F 6. Trailing ratios: ROE 7.1% · ROA 5.1% · current ratio 2.87 · earnings yield 3.1% · free-cash-flow yield 5.3%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 33.04 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TRUMY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TRUMY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Terumo (TRUMY)?
Terumo Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
What does Terumo’s Cardiac and Vascular business sell?
It supplies guidewires, catheters, stents, intravascular imaging, neurovascular devices, stroke-treatment tools, cardiopulmonary systems, and vascular graft products. Demand is linked to cardiovascular and cerebrovascular procedures rather than routine equipment replacement alone.
How does Terumo’s Blood and Cell Technologies business make money?
The business sells blood bags, collection and automated processing systems, pathogen-reduction tools, apheresis systems, and cell-expansion platforms. Its commercial exposure follows blood collection, component processing, therapeutic apheresis, and cell-management activity.
Why does Terumo manufacture prefillable syringes for pharmaceutical companies?
Prefillable syringes and needles place Terumo inside pharmaceutical drug-packaging programs as a contract manufacturer. That activity differs from selling devices directly for procedures because demand follows the packaging and delivery requirements of drugmakers.
What is the TRUMY stock price today?
The last price recorded for Terumo Corporation (TRUMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com